Could a diabetes drug help heal fatty livers?
NCT ID NCT03884075
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 9 times
Summary
This study looks at how the liver responds to food and a drug called semaglutide in people with non-alcoholic fatty liver disease (NAFLD). About 84 adults, including healthy volunteers, will take part. Researchers will check if semaglutide can reduce liver fat and damage over 30 weeks of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could immune cells in fat hold the key to Obesity-Related disease?
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can fatty liver in children lead to serious liver disease? a Long-Term study aims to find out
- Can a scan replace the needle? ultrasound and MRI put to the test against liver biopsy for fatty liver disease
- Can fish oil shrink a fatty liver?